Negative WPI Set To Trigger Price Cuts In India?
This article was originally published in PharmAsia News
Executive Summary
The going has generally been tough for pharmaceutical firms in India this past year, stretched by volatility in certain emerging markets and plant woes, but the industry there should probably steel itself for yet more pain on its home turf.
You may also be interested in...
New Price Headwinds Swirl In India
Fresh efforts to rein in drug prices may be on the cards in India, as the government evaluates linking prices of all medicines to a wholesale price index. Industry anticipates "major disruption" if the proposal goes through.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet